IGF-IR and its inhibitors in gastrointestinal carcinomas

Xiao Hong Bao, Yoshio Nomoto, Hui Fang Hao, Nobuyuki Watanabe, Kazufumi Sakurama, Kazuhiro Noma, Takayuki Motoki, Yasuko Tomono, Takuya Fukazawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Munenori Takaoka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalOncology Letters
Volume1
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Carcinoma
Neoplasms
IGF Type 1 Receptor
Feasibility Studies
Protein-Tyrosine Kinases
Carcinogenesis
Monoclonal Antibodies
Pathology
Therapeutics

Keywords

  • Cancer therapy
  • Gastrointestinal carcinoma
  • Monoclonal antibody
  • Type I insulin-like growth factor receptor
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bao, X. H., Nomoto, Y., Hao, H. F., Watanabe, N., Sakurama, K., Noma, K., ... Takaoka, M. (2010). IGF-IR and its inhibitors in gastrointestinal carcinomas. Oncology Letters, 1(1), 195-201. https://doi.org/10.3892/ol_00000036

IGF-IR and its inhibitors in gastrointestinal carcinomas. / Bao, Xiao Hong; Nomoto, Yoshio; Hao, Hui Fang; Watanabe, Nobuyuki; Sakurama, Kazufumi; Noma, Kazuhiro; Motoki, Takayuki; Tomono, Yasuko; Fukazawa, Takuya; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Matsuoka, Junji; Takaoka, Munenori.

In: Oncology Letters, Vol. 1, No. 1, 01.2010, p. 195-201.

Research output: Contribution to journalArticle

Bao, XH, Nomoto, Y, Hao, HF, Watanabe, N, Sakurama, K, Noma, K, Motoki, T, Tomono, Y, Fukazawa, T, Shirakawa, Y, Yamatsuji, T, Matsuoka, J & Takaoka, M 2010, 'IGF-IR and its inhibitors in gastrointestinal carcinomas', Oncology Letters, vol. 1, no. 1, pp. 195-201. https://doi.org/10.3892/ol_00000036
Bao XH, Nomoto Y, Hao HF, Watanabe N, Sakurama K, Noma K et al. IGF-IR and its inhibitors in gastrointestinal carcinomas. Oncology Letters. 2010 Jan;1(1):195-201. https://doi.org/10.3892/ol_00000036
Bao, Xiao Hong ; Nomoto, Yoshio ; Hao, Hui Fang ; Watanabe, Nobuyuki ; Sakurama, Kazufumi ; Noma, Kazuhiro ; Motoki, Takayuki ; Tomono, Yasuko ; Fukazawa, Takuya ; Shirakawa, Yasuhiro ; Yamatsuji, Tomoki ; Matsuoka, Junji ; Takaoka, Munenori. / IGF-IR and its inhibitors in gastrointestinal carcinomas. In: Oncology Letters. 2010 ; Vol. 1, No. 1. pp. 195-201.
@article{fbb7ae9eb8684bf5b5e1b8b5a02f71a3,
title = "IGF-IR and its inhibitors in gastrointestinal carcinomas",
abstract = "The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.",
keywords = "Cancer therapy, Gastrointestinal carcinoma, Monoclonal antibody, Type I insulin-like growth factor receptor, Tyrosine kinase inhibitor",
author = "Bao, {Xiao Hong} and Yoshio Nomoto and Hao, {Hui Fang} and Nobuyuki Watanabe and Kazufumi Sakurama and Kazuhiro Noma and Takayuki Motoki and Yasuko Tomono and Takuya Fukazawa and Yasuhiro Shirakawa and Tomoki Yamatsuji and Junji Matsuoka and Munenori Takaoka",
year = "2010",
month = "1",
doi = "10.3892/ol_00000036",
language = "English",
volume = "1",
pages = "195--201",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - IGF-IR and its inhibitors in gastrointestinal carcinomas

AU - Bao, Xiao Hong

AU - Nomoto, Yoshio

AU - Hao, Hui Fang

AU - Watanabe, Nobuyuki

AU - Sakurama, Kazufumi

AU - Noma, Kazuhiro

AU - Motoki, Takayuki

AU - Tomono, Yasuko

AU - Fukazawa, Takuya

AU - Shirakawa, Yasuhiro

AU - Yamatsuji, Tomoki

AU - Matsuoka, Junji

AU - Takaoka, Munenori

PY - 2010/1

Y1 - 2010/1

N2 - The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.

AB - The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.

KW - Cancer therapy

KW - Gastrointestinal carcinoma

KW - Monoclonal antibody

KW - Type I insulin-like growth factor receptor

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77955753972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955753972&partnerID=8YFLogxK

U2 - 10.3892/ol_00000036

DO - 10.3892/ol_00000036

M3 - Article

VL - 1

SP - 195

EP - 201

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -